MRC1 and central nervous system cancer: We showed that CD206-targeted MRI can detect CD206+ TAMs, differentiate Mrc1+/+, Mrc1+/-, and Mrc1-/- mice, and track treatment changes of CD206+ TAMs treated by D-mannose in a mouse model of glioma (Figure 3).